AGMB — Agomab Therapeutics NV Balance Sheet
0.000.00%
Annual balance sheet for Agomab Therapeutics NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 27.7 | 122 | 171 | 117 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 3.33 | 17 | 2.12 | 4.08 |
| Total Other Current Assets | ||||
| Total Current Assets | 71.1 | 139 | 174 | 121 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 0.062 | 1.61 | 1.99 | 1.59 |
| Net Goodwill | ||||
| Net Intangible Assets | ||||
| Long Term Investments | ||||
| Long Term Notes Receivable | ||||
| Other Long Term Assets | ||||
| Total Assets | 101 | 171 | 206 | 154 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 29.7 | 10.9 | 9.13 | 18.6 |
| Long Term Debt | ||||
| Capital Lease Obligations | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Deferred Income Tax | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 34.7 | 19.8 | 18.3 | 22.8 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 66.2 | 151 | 188 | 131 |
| Total Liabilities & Shareholders' Equity | 101 | 171 | 206 | 154 |
| Total Common Shares Outstanding |